Improving the risk assessment of engineered nanomaterials (ENMs) requires that uncertainties in their potential releases during their complete life cycle are quantified and, as far as possible, reduced.
No takes yet. Share an insight, caveat, or question.
Adam et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: